First Antibacterial for VREF
- 3 November 1999
- journal article
- other
- Published by American Medical Association (AMA) in JAMA
- Vol. 282 (17) , 1613
- https://doi.org/10.1001/jama.282.17.1613-jfd90009-2-1
Abstract
The FDA has approved Synercid (Rhone-Poulenc Rorer, Collegeville, Pa), the first antimicrobial drug to treat infections associated with vancomycin-resistant Enterococcus faecium (VREF) bacteremia. Synercid, a combination of quinupristin and dalfopristin, also received approval for the treatment of complicated skin and skin structure (SST) infections (such as cellulitis/erysipelas, postoperative infections, and traumatic wound infections) caused by methicillin-susceptible Staphylococcus aureus and Streptococcus pyogenes.Keywords
This publication has 0 references indexed in Scilit: